A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-AD5
- Sponsors Eli Lilly and Company
- 21 Nov 2019 Planned End Date changed from 20 Aug 2021 to 2 Sep 2021.
- 21 Nov 2019 Planned primary completion date changed from 15 Nov 2019 to 28 Nov 2019.
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.